Pelacarsen Market Size, Forecast, and Emerging Insight - 2032
상품코드:1462310
리서치사:DelveInsight
발행일:On Demand Report
페이지 정보:영문 30 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
약제 요약
Pelacarsen(TQJ230)은 IONIS-APO(a)-LRx, AKCEA-APO(a)-LRx로도 알려진 시험 중인 항센스 의약품으로 간에서 아포지단백(a)을 감소시키도록 설계되었으며, Lp(a)의 상승은 관상동맥질환, 심장마비, 뇌졸중 및 말초동맥질환의 독립적인 유전적 원인으로 인식되고 있습니다. 현재 Lp(a) 수치를 유의하게 낮출 수 있는 효과적인 약물은 없으며, Lp(a) 수치는 출생시 결정되며, 식습관이나 운동과 같은 생활습관 개선은 Lp(a) 수치에 영향을 미치지 않으며, LDL-C를 조절할 수 있는 환자라도 Lp(a) 수치가 높으면 심혈관 질환의 위험이 여전히 높습니다. 심혈관 질환의 위험은 여전히 높습니다.
Pelacarsen은 Lp(a) 수치가 높아 CVD 위험이 높은 환자를 대상으로 개발되고 있으며, Lp(a) 생성을 선택적으로 강력하게 억제하도록 설계된 임상 개발 중인 최초의 약물입니다.
노바티스의 2022년 3분기 투자자 프레젠테이션에 따르면 노바티스는 2025년에 펠라카르센을 신청하고 데이터를 발표할 예정입니다.
주요 7 시장(미국·독일·프랑스·이탈리아·스페인·영국·일본)의 심근경색용 Pelacarsen에 대해 조사분석했으며, 작용기서, 용법과 용량, 연구개발 활동에 관한 인사이트, 매출의 예측 등을 제공하고 있습니다.
목차
제1장 리포트의 서론
제2장 심근경색에서 Pelacarsen의 개요
제품의 상세
임상 개발
임상 연구
임상시험 정보
안전성과 유효성
기타 개발 활동
제품 개요
제3장 경쟁 구도(출시 치료법)
제4장 경쟁 구도(후기 신치료법)
제5장 Pelacarsen 시장 평가
심근경색에서 Pelacarsen의 시장 전망
주요 7 시장 분석
주요 7 시장의 심근경색용 Pelacarsen의 시장 규모
시장 분석 : 국가별
미국의 심근경색용 Pelacarsen의 시장 규모
독일의 심근경색용 Pelacarsen의 시장 규모
영국의 심근경색용 Pelacarsen의 시장 규모
제6장 SWOT 분석
제7장 애널리스트의 견해
제8장 부록
제9장 DelveInsight의 서비스 내용
제10장 면책사항
제11장 DelveInsight 소개
제12장 리포트 구입 옵션
KSA
영문 목차
영문목차
"Pelacarsen Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about pelacarsen for myocardial infarction in the seven major markets. A detailed picture of the pelacarsen for myocardial infarction in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the pelacarsen for myocardial infarction. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the pelacarsen market forecast analysis for myocardial infarction in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in myocardial infarction.
Drug Summary:
Pelacarsen (TQJ230), also known as IONIS-APO(a)-LRx, AKCEA-APO(a)-LRx, and TQJ230, is an investigational antisense medicine designed to reduce apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a), or Lp (a)-a very atherogenic and thrombogenic form of LDL. Elevated Lp (a) is recognized as an independent genetic cause of coronary artery disease, heart attack, stroke, and peripheral arterial disease. Currently, there is no effective drug therapy to significantly lower elevated levels of Lp (a). Lp (a) levels are determined at birth; lifestyle modification, including diet and exercise, does not impact Lp (a) levels. Even patients who can control their LDL-C remain at high risk of cardiovascular events if they have high levels of Lp (a).
Pelacarsen is being developed for patients at significant risk of CVD because of their elevated Lp (a). Pelacarsen is the first drug in clinical development designed to selectively and robustly inhibit the production of Lp (a).
As per the company's Q3 2022 investor presentation, Novartis plans filing as well as data readouts of pelacarsen in 2025.
Scope of the Report:
The report provides insights into:
A comprehensive product overview including the pelacarsen description, mechanism of action, dosage and administration, research and development activities in myocardial infarction.
Elaborated details on pelacarsen regulatory milestones and other development activities have been provided in this report.
The report also highlights the pelacarsen research and development activities in myocardial infarction across the United States, Europe and Japan.
The report also covers the patents information with expiry timeline around pelacarsen.
The report contains forecasted sales of pelacarsen for myocardial infarction till 2032.
Comprehensive coverage of the late-stage emerging therapies for myocardial infarction.
The report also features the SWOT analysis with analyst views for pelacarsen in myocardial infarction.
Methodology:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Pelacarsen Analytical Perspective by DelveInsight
In-depth Pelacarsen Market Assessment
This report provides a detailed market assessment of pelacarsen for myocardial infarction in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.
Pelacarsen Clinical Assessment
The report provides the clinical trials information of pelacarsen for myocardial infarction covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights:
In the coming years, the market scenario for myocardial infarction is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence pelacarsen dominance.
Other emerging products for myocardial infarction are expected to give tough market competition to pelacarsen and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of pelacarsen in myocardial infarction.
Our in-depth analysis of the forecasted sales data of pelacarsen from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the pelacarsen in myocardial infarction.
Key Questions:
What is the product type, route of administration and mechanism of action of pelacarsen?
What is the clinical trial status of the study related to pelacarsen in myocardial infarction and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the pelacarsen development?
What are the key designations that have been granted to pelacarsen for myocardial infarction?
What is the forecasted market scenario of pelacarsen for myocardial infarction?
What are the forecasted sales of pelacarsen in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
What are the other emerging products available and how are these giving competition to pelacarsen for myocardial infarction?
Which are the late-stage emerging therapies under development for the treatment of myocardial infarction?
